Alphatec (ATEC) Stock Price Sinks After Q3 Results Cut Guidance

Alphatec Holdings just dropped its Q3 2026 scorecard and the share price did not hesitate. The stock collapsed 38% on Friday to US$7.05, reacting far more violently than the headline numbers suggest.

Revenue reached US$221.2m and the company still reported a loss, yet losses narrowed sharply versus recent quarters. At the same time, adjusted EBITDA margin improved to 17%, reflecting firmer profitability signals even as management cut full year guidance. The market traded the guidance reset. The financials pointed to a story that is more about pressure on expectations than a sudden break in the spinal hardware thesis.

Love Alphatec Holdings' improving EBITDA margin but worried about the guidance reset and ongoing losses? Compare it with our list of solid balance sheet and fundamentals stocks (25 results) for ideas that pair revenue traction with sturdier profitability profiles.

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$221.2m vs. US$196.5m (up roughly 13%)
• Net Loss (Q3 2026 vs. Q3 2025): loss of US$5.5m vs. loss of US$28.6m (loss narrowed sharply)
• Basic EPS (Q3 2026 vs. Q3 2025): loss of US$0.03 per share vs. loss of US$0.19 per share (per share loss reduced)
• Adjusted EBITDA Margin (Q3 2026 vs. Q3 2025): 17% vs. roughly 13% (margin expanded by about 400 bps)

Surgeon growth is strong, but biologics dollars are slipping. Ask Charlie what’s really behind Alphatec’s weaker biologics revenue.

Alphatec Bull Case Hinges On Utilization Proof Points

The optimistic view rests on Alphatec Holdings turning its ecosystem into sustained surgeon behavior change.

"The main thing that has to go right is that lateral-led adoption of the PTP platform and EOSedge access to leading institutions continue to translate into higher surgeon utilization across procedures and geographies without stalling due to execution issues or legal overhangs."

Q3 gives that idea mixed but meaningful support. Surgical case volumes climbed about 20% and new surgeon additions advanced roughly 25%, which signals broadening use of the platform. Hardware revenue, up mid teens, shows those surgeons are not just trialing the tools. At the same time, lower revenue per case and softer thoracolumbar activity reveal that higher utilization is not yet translating cleanly into procedure economics.

The price and this Narrative do not agree. → Uncover what this Narrative says Alphatec Holdings is actually worth.

Alphatec Bear Case On Pricing Gains Traction

Bearish investors argued that Alphatec Holdings could grow procedures yet lose economic weight per surgery.

"While surgeon users and surgical cases are growing at around 20% year over year, the roughly 2.7% decline in average revenue per case in Q2 2026 after a similar decline in Q1 shows that mix toward cervical and international procedures, together with weaker biologics attachment, could offset volume growth and restrict total revenue and EBITDA expansion."

Q3 results push this concern forward, not backward. Revenue per case fell about 5% and biologics revenue slipped by roughly US$1m even as surgical hardware and cases rose strongly. Management cut full year revenue and EBITDA guidance and now assumes further revenue per case pressure. That combination supports the pricing and mix part of the bear story, even while overall volumes remain healthy.

Hunt For Mispriced Earnings Power

Alphatec Holdings just showed how quickly sentiment can change when expectations clash with guidance. The real opportunity is spotting stocks that could be undervalued before those expectations adjust.

• Company 1 - 34% below our estimate - converts long term optical and solar agreements and customer prepayments into a higher margin manufacturing plan.
• Company 2 - 38% below our estimate - expands a specialty film and coatings manufacturing base while building higher margin installation and dealership channels.
• Company 3 - 31% below our estimate - builds large AI infrastructure clusters that support demanding generative models through a key partnership.

That is three of the list. See the full list of 29 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com